The Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB) research study is testing whether a medication called tirzepatide can help people who are already receiving buprenorphine treatment for opioid use disorder (OUD). Tirzepatide is a GLP-1 usually used to treat diabetes and help with weight loss, but researchers are exploring whether it can also improve outcomes for people in recovery from opioid use.

The study will include about 310 participants across the United States who are already taking buprenorphine. Half will receive tirzepatide, and half will get a placebo (a treatment with no active medicine). Everyone will continue their regular care. Study participation lasts around 7 months, and participants will have weekly visits and wear a Fitbit to track sleep. Researchers will look at how tirzepatide affects treatment retention, drug use, and sleep quality.